Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells

Non-small cell lung cancer (NSCLC) is one of the most common forms and leading causes of cancer-related mortality worldwide, and discovery of new effective drugs still remains imperative to improve the survival rate. Nagilactone E (NLE) is a natural product isolated from Podocarpus nagi seeds, which...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2018-07, Vol.830, p.17-25
Hauptverfasser: Zhang, Le-Le, Feng, Zhe-Ling, Su, Min-Xia, Jiang, Xiao-Ming, Chen, Xiuping, Wang, Yitao, Li, Ao, Lin, Li-Gen, Lu, Jin-Jian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 25
container_issue
container_start_page 17
container_title European journal of pharmacology
container_volume 830
creator Zhang, Le-Le
Feng, Zhe-Ling
Su, Min-Xia
Jiang, Xiao-Ming
Chen, Xiuping
Wang, Yitao
Li, Ao
Lin, Li-Gen
Lu, Jin-Jian
description Non-small cell lung cancer (NSCLC) is one of the most common forms and leading causes of cancer-related mortality worldwide, and discovery of new effective drugs still remains imperative to improve the survival rate. Nagilactone E (NLE) is a natural product isolated from Podocarpus nagi seeds, which has been used as raw materials for edible oil and industrial oil extraction. This study aimed to investigate the anticancer potential of NLE against NSCLC A549 and NCI-H1975 cells. MTT assay revealed that NLE inhibited the proliferation of A549 and NCI-H1975 cells with IC50s of 5.18 ± 0.49 and 3.57 ± 0.29 μM, respectively. NLE treatment inhibited clone formation in both cancer cell lines. Cell cycle analysis indicated that NLE treatment effectively induced G2 phase cell cycle arrest in A549 and NCI-H1975 cells. NLE downregulated the phosphorylation of cdc2 (Tyr15) and cdc25C (Ser216) as well as the expression level of the protein kinase Wee1 in concentration- and time-dependent manners. In addition, NLE treatment decreased the protein level of Cyclin B1 as well as its nuclear localization, which might decrease the activity of the Cyclin B1/cdc2 complex and induce G2 phase arrest. Long-term NLE treatment also induced caspase-dependent cell apoptosis, as evidenced by increase in Annexin V positive cells and the cleavage of PARP. To sum, NLE inhibited proliferation, induced G2 phase arrest, and triggered caspase-dependent apoptosis in NSCLC cells, suggesting it to be a potential leading compound for cancer treatment. [Display omitted]
doi_str_mv 10.1016/j.ejphar.2018.04.020
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2029635910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299918302371</els_id><sourcerecordid>2029635910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-b5e44278ec59f22998a88a4bd4057f00ce5b3fb3a54e6eb7e324c0fba73cc0093</originalsourceid><addsrcrecordid>eNp9kEFv2zAMhYWhw5Jm-wdFoWMvdilZjq3LgDZL0wEBdtnOgizTmQJHyiS7Q_795CXtsScC5Hvk40fIDYOcAVve73PcH3_rkHNgdQ4iBw4fyJzVlcygYvyKzAGYyLiUckauY9wDQCl5-YnMuFzWwHk9J6dv_q8LuBt7PVjvqO_o6mR66-gjowdsrR4wUqd3ttdm8A7pOrOuHQ22dMNpChCRGux7apINqQ4B40CT33mXxYOeJtO4H92OGu0Mhv-N-Jl87HQf8culLsivp_XP1XO2_bH5vnrYZqZY8iFrShSCVzWaUnY8PVPrutaiaQWUVQdgsGyKril0KXCJTYUFFwa6RleFMQCyWJC7895j8H_GFE4dbJwSaId-jIpDolGUkkGSirPUBB9jwE4dgz3ocFIM1ARd7dUZupqgKxAqQU-228uFsUnI3kyvlJPg61mA6c8Xi0FFYzGhaG1AM6jW2_cv_AMkDJV1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2029635910</pqid></control><display><type>article</type><title>Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Zhang, Le-Le ; Feng, Zhe-Ling ; Su, Min-Xia ; Jiang, Xiao-Ming ; Chen, Xiuping ; Wang, Yitao ; Li, Ao ; Lin, Li-Gen ; Lu, Jin-Jian</creator><creatorcontrib>Zhang, Le-Le ; Feng, Zhe-Ling ; Su, Min-Xia ; Jiang, Xiao-Ming ; Chen, Xiuping ; Wang, Yitao ; Li, Ao ; Lin, Li-Gen ; Lu, Jin-Jian</creatorcontrib><description>Non-small cell lung cancer (NSCLC) is one of the most common forms and leading causes of cancer-related mortality worldwide, and discovery of new effective drugs still remains imperative to improve the survival rate. Nagilactone E (NLE) is a natural product isolated from Podocarpus nagi seeds, which has been used as raw materials for edible oil and industrial oil extraction. This study aimed to investigate the anticancer potential of NLE against NSCLC A549 and NCI-H1975 cells. MTT assay revealed that NLE inhibited the proliferation of A549 and NCI-H1975 cells with IC50s of 5.18 ± 0.49 and 3.57 ± 0.29 μM, respectively. NLE treatment inhibited clone formation in both cancer cell lines. Cell cycle analysis indicated that NLE treatment effectively induced G2 phase cell cycle arrest in A549 and NCI-H1975 cells. NLE downregulated the phosphorylation of cdc2 (Tyr15) and cdc25C (Ser216) as well as the expression level of the protein kinase Wee1 in concentration- and time-dependent manners. In addition, NLE treatment decreased the protein level of Cyclin B1 as well as its nuclear localization, which might decrease the activity of the Cyclin B1/cdc2 complex and induce G2 phase arrest. Long-term NLE treatment also induced caspase-dependent cell apoptosis, as evidenced by increase in Annexin V positive cells and the cleavage of PARP. To sum, NLE inhibited proliferation, induced G2 phase arrest, and triggered caspase-dependent apoptosis in NSCLC cells, suggesting it to be a potential leading compound for cancer treatment. [Display omitted]</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2018.04.020</identifier><identifier>PMID: 29680228</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Apoptosis ; Cell cycle ; Cyclin B1 ; Nagilactone E ; Non-small cell lung cancer</subject><ispartof>European journal of pharmacology, 2018-07, Vol.830, p.17-25</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-b5e44278ec59f22998a88a4bd4057f00ce5b3fb3a54e6eb7e324c0fba73cc0093</citedby><cites>FETCH-LOGICAL-c362t-b5e44278ec59f22998a88a4bd4057f00ce5b3fb3a54e6eb7e324c0fba73cc0093</cites><orcidid>0000-0003-2675-7645</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2018.04.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29680228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Le-Le</creatorcontrib><creatorcontrib>Feng, Zhe-Ling</creatorcontrib><creatorcontrib>Su, Min-Xia</creatorcontrib><creatorcontrib>Jiang, Xiao-Ming</creatorcontrib><creatorcontrib>Chen, Xiuping</creatorcontrib><creatorcontrib>Wang, Yitao</creatorcontrib><creatorcontrib>Li, Ao</creatorcontrib><creatorcontrib>Lin, Li-Gen</creatorcontrib><creatorcontrib>Lu, Jin-Jian</creatorcontrib><title>Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Non-small cell lung cancer (NSCLC) is one of the most common forms and leading causes of cancer-related mortality worldwide, and discovery of new effective drugs still remains imperative to improve the survival rate. Nagilactone E (NLE) is a natural product isolated from Podocarpus nagi seeds, which has been used as raw materials for edible oil and industrial oil extraction. This study aimed to investigate the anticancer potential of NLE against NSCLC A549 and NCI-H1975 cells. MTT assay revealed that NLE inhibited the proliferation of A549 and NCI-H1975 cells with IC50s of 5.18 ± 0.49 and 3.57 ± 0.29 μM, respectively. NLE treatment inhibited clone formation in both cancer cell lines. Cell cycle analysis indicated that NLE treatment effectively induced G2 phase cell cycle arrest in A549 and NCI-H1975 cells. NLE downregulated the phosphorylation of cdc2 (Tyr15) and cdc25C (Ser216) as well as the expression level of the protein kinase Wee1 in concentration- and time-dependent manners. In addition, NLE treatment decreased the protein level of Cyclin B1 as well as its nuclear localization, which might decrease the activity of the Cyclin B1/cdc2 complex and induce G2 phase arrest. Long-term NLE treatment also induced caspase-dependent cell apoptosis, as evidenced by increase in Annexin V positive cells and the cleavage of PARP. To sum, NLE inhibited proliferation, induced G2 phase arrest, and triggered caspase-dependent apoptosis in NSCLC cells, suggesting it to be a potential leading compound for cancer treatment. [Display omitted]</description><subject>Apoptosis</subject><subject>Cell cycle</subject><subject>Cyclin B1</subject><subject>Nagilactone E</subject><subject>Non-small cell lung cancer</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kEFv2zAMhYWhw5Jm-wdFoWMvdilZjq3LgDZL0wEBdtnOgizTmQJHyiS7Q_795CXtsScC5Hvk40fIDYOcAVve73PcH3_rkHNgdQ4iBw4fyJzVlcygYvyKzAGYyLiUckauY9wDQCl5-YnMuFzWwHk9J6dv_q8LuBt7PVjvqO_o6mR66-gjowdsrR4wUqd3ttdm8A7pOrOuHQ22dMNpChCRGux7apINqQ4B40CT33mXxYOeJtO4H92OGu0Mhv-N-Jl87HQf8culLsivp_XP1XO2_bH5vnrYZqZY8iFrShSCVzWaUnY8PVPrutaiaQWUVQdgsGyKril0KXCJTYUFFwa6RleFMQCyWJC7895j8H_GFE4dbJwSaId-jIpDolGUkkGSirPUBB9jwE4dgz3ocFIM1ARd7dUZupqgKxAqQU-228uFsUnI3kyvlJPg61mA6c8Xi0FFYzGhaG1AM6jW2_cv_AMkDJV1</recordid><startdate>20180705</startdate><enddate>20180705</enddate><creator>Zhang, Le-Le</creator><creator>Feng, Zhe-Ling</creator><creator>Su, Min-Xia</creator><creator>Jiang, Xiao-Ming</creator><creator>Chen, Xiuping</creator><creator>Wang, Yitao</creator><creator>Li, Ao</creator><creator>Lin, Li-Gen</creator><creator>Lu, Jin-Jian</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2675-7645</orcidid></search><sort><creationdate>20180705</creationdate><title>Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells</title><author>Zhang, Le-Le ; Feng, Zhe-Ling ; Su, Min-Xia ; Jiang, Xiao-Ming ; Chen, Xiuping ; Wang, Yitao ; Li, Ao ; Lin, Li-Gen ; Lu, Jin-Jian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-b5e44278ec59f22998a88a4bd4057f00ce5b3fb3a54e6eb7e324c0fba73cc0093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Apoptosis</topic><topic>Cell cycle</topic><topic>Cyclin B1</topic><topic>Nagilactone E</topic><topic>Non-small cell lung cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Le-Le</creatorcontrib><creatorcontrib>Feng, Zhe-Ling</creatorcontrib><creatorcontrib>Su, Min-Xia</creatorcontrib><creatorcontrib>Jiang, Xiao-Ming</creatorcontrib><creatorcontrib>Chen, Xiuping</creatorcontrib><creatorcontrib>Wang, Yitao</creatorcontrib><creatorcontrib>Li, Ao</creatorcontrib><creatorcontrib>Lin, Li-Gen</creatorcontrib><creatorcontrib>Lu, Jin-Jian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Le-Le</au><au>Feng, Zhe-Ling</au><au>Su, Min-Xia</au><au>Jiang, Xiao-Ming</au><au>Chen, Xiuping</au><au>Wang, Yitao</au><au>Li, Ao</au><au>Lin, Li-Gen</au><au>Lu, Jin-Jian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2018-07-05</date><risdate>2018</risdate><volume>830</volume><spage>17</spage><epage>25</epage><pages>17-25</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Non-small cell lung cancer (NSCLC) is one of the most common forms and leading causes of cancer-related mortality worldwide, and discovery of new effective drugs still remains imperative to improve the survival rate. Nagilactone E (NLE) is a natural product isolated from Podocarpus nagi seeds, which has been used as raw materials for edible oil and industrial oil extraction. This study aimed to investigate the anticancer potential of NLE against NSCLC A549 and NCI-H1975 cells. MTT assay revealed that NLE inhibited the proliferation of A549 and NCI-H1975 cells with IC50s of 5.18 ± 0.49 and 3.57 ± 0.29 μM, respectively. NLE treatment inhibited clone formation in both cancer cell lines. Cell cycle analysis indicated that NLE treatment effectively induced G2 phase cell cycle arrest in A549 and NCI-H1975 cells. NLE downregulated the phosphorylation of cdc2 (Tyr15) and cdc25C (Ser216) as well as the expression level of the protein kinase Wee1 in concentration- and time-dependent manners. In addition, NLE treatment decreased the protein level of Cyclin B1 as well as its nuclear localization, which might decrease the activity of the Cyclin B1/cdc2 complex and induce G2 phase arrest. Long-term NLE treatment also induced caspase-dependent cell apoptosis, as evidenced by increase in Annexin V positive cells and the cleavage of PARP. To sum, NLE inhibited proliferation, induced G2 phase arrest, and triggered caspase-dependent apoptosis in NSCLC cells, suggesting it to be a potential leading compound for cancer treatment. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29680228</pmid><doi>10.1016/j.ejphar.2018.04.020</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2675-7645</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2018-07, Vol.830, p.17-25
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_2029635910
source Elsevier ScienceDirect Journals Complete
subjects Apoptosis
Cell cycle
Cyclin B1
Nagilactone E
Non-small cell lung cancer
title Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A51%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Downregulation%20of%20Cyclin%20B1%20mediates%20nagilactone%20E-induced%20G2%20phase%20cell%20cycle%20arrest%20in%20non-small%20cell%20lung%20cancer%20cells&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Zhang,%20Le-Le&rft.date=2018-07-05&rft.volume=830&rft.spage=17&rft.epage=25&rft.pages=17-25&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2018.04.020&rft_dat=%3Cproquest_cross%3E2029635910%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2029635910&rft_id=info:pmid/29680228&rft_els_id=S0014299918302371&rfr_iscdi=true